Prothena Gross Profit 2011-2022 | PRTA
Prothena gross profit from 2011 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Prothena Annual Gross Profit
(Millions of US $) |
| 2021 |
$201 |
| 2020 |
$1 |
| 2019 |
$1 |
| 2018 |
$1 |
| 2017 |
$28 |
| 2016 |
$1 |
| 2015 |
$2 |
| 2014 |
$51 |
| 2013 |
$1 |
| 2012 |
$3 |
| 2011 |
$1 |
| 2010 |
$1 |
Prothena Quarterly Gross Profit
(Millions of US $) |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$1 |
| 2021-09-30 |
$139 |
| 2021-06-30 |
$60 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$0 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$0 |
| 2019-09-30 |
$0 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
$0 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$27 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$0 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$1 |
| 2014-06-30 |
$15 |
| 2014-03-31 |
$32 |
| 2013-12-31 |
$0 |
| 2013-09-30 |
$0 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$1 |
| 2012-06-30 |
$1 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.268B |
$0.201B |
|
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
|
